European Journal of Cancer
Volume 37, Issue 14 , Pages 1752-1758 , September 2001

Modelling the future costs of breast screening

  • K. Johnston

      Affiliations

    • Corresponding Author InformationTel.: +44-1865-226-692; fax +44-1865-226-842

Received 11 May 2001 ,Accepted 30 May 2001.

References 

  1. Brown ML, Fintor L. Cost-effectiveness of breast cancer screening (preliminary results of a systematic review of the literature). Breast Cancer Res. Treat. 1993;25:113–118
  2. de Koning HJ, Van Ineveld BM, De Haes JCJM, Van Oortmarssen GJ, Klijn JGM, Van der Maas PJ. Advanced breast cancer and its prevention by screening. Br. J. Cancer. 1992;65:950–955
  3. Butler JR, Furnival CM, Hart RF. The costs of treating breast cancer in Australia and the implications for breast cancer screening. Australian and New Zealand J. Surg. 1995;65:485–491
  4. Salkeld G, Gerard K. Will early detection of breast cancer reduce the costs of treatment?. Australian J. Public Health. 1994;18:388–393
  5. Wolstenholme JL, Smith SJ, Whynes DK. The costs of treating breast cancer in the United Kingdom (implications for screening). Int. J. Technol. Assess. Health Care. 1998;14:277–289
  6. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in Health and Medicine. New York: Oxford University Press; 1996;
  7. Meltzer D. Accounting for future costs in medical cost-effectiveness analysis. J. Health Econ. 1997;16:33–64
  8. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. Oxford: Oxford University Press; 1997;
  9. Mushlin AI, Fintor L. Is screening for breast cancer cost-effective?. Cancer. 1992;69(Suppl.):1957–1962
  10. Gravelle H, Simpson PR, Chamberlain J. Breast cancer screening and health service costs. J. Health Econ. 1982;1:185–207
  11. Johannesson M, Meltzer D, O'Conor RM. Incorporating future costs in medical cost-effectiveness analysis (implications for the cost-effectiveness of the treatment of hypertension). Med. Decision Making. 1997;17:382–389
  12. Department of Health. Economic Appraisal of the Health Effects of Air Pollution. London: The Stationery Office; 1999;
  13. Todd JH, Dowle C, Williams MR, et al.  Confirmation of a prognostic index in primary breast cancer. Br. J. Cancer. 1987;56:489–492
  14. Blamey RW. The design and clinical use of the Nottingham prognostic index in breast cancer. The Breast 1996, 5, 156–157 (abstr).
  15. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. 1. The value of histological grade in breast cancer (experience from a large study with long term follow up). Histopathol. 1991;19:403–410
  16. Tabar L, Fagerberg CJ, Gad A, et al.  Reduction in mortality from breast cancer after mass screening with mammography. Randomised trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare. Lancet. 1985;1:829–832
  17. Blamey RW, Day N, Young R, Duffy S, Pinder S. The UKCCCR trial of frequency of breast screening. The Breast 1999, 8, 215 (abstr).
  18. Sonnenberg FA, Beck JR. Markov models in medical decision making. Med. Decision Making. 1993;13:322–338
  19. Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoecon. 1999;13:397–409
  20. Hillner BE, Smith TJ. Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. N. Engl. J. Med. 1991;324:160–168
  21. HM Treasury. Appraisal and Evaluation in Central Government (Treasury Guidance). London: The Stationery Office; 1997;
  22. Department of Health. The Government's Expenditure Plans 1999–2000. London: The Stationery Office; 1999;
  23. Blamey RW, Wilson ARM, Patnick J. Screening for breast cancer. BMJ. 2000;321:689–693
  24. Johnston K, Gerard K, Morton A, Brown J. NHS Costs for the Breast Screening Frequency and Age Trials. Health Economics Research Group Discussion paper number 16. Brunel University, 1996.
  25. Will BP, Le Petit C, Berthelot JM, Tomiak EM, Verma S, Evans WK. Diagnostic and therapeutic approaches for nonmetastatic breast cancer in Canada, and their associated costs. Br. J. Cancer. 1999;79:1428–1436
  26. Legoretta AP, Brooks RJ, Leibowitz AN, Solin LJ. Cost of breast cancer treatment (a 4-year longitudinal study). Annals of Inter. Med. 1996;156:2197–2201
  27. Hillner BE, Smith TJ. Should women with node negative breast cancer receive adjuvant chemotherapy?—Insights from a decision analysis model. Breast Cancer Res. Treat. 1992;23:17–27
  28. Daly E, Roche M, Barlow D, Gray A, McPherson K, Vessey M. HRT (an analysis of benefits, risks and costs). Br. Med. Bull. 1992;48:368–400
  29. Office of Health Economics. Compendium of Health Statistics. London: Office of Health Economics; 1999;
  30. O'Rourke S, Galea MH, Morgan D, et al.  Local recurrence after simple mastectomy. British Journal of Surgery. 1994;84:386–389
  31. Sibbering DM, Galea MH, Morgan DAL, et al.  Safe selection criteria for breast conservation without radical excision in primary operable invasive breast cancer. Eur. J. Cancer. 1995;31:2191–2195
  32. Robertson JFR, Whynes DK, Dixon A, Blamey RW. Potential for cost economies in guiding therapy in patients with metastatic breast cancer. Br. J. Cancer. 1995;72:174–177

PII: S0959-8049(01)00202-7

European Journal of Cancer
Volume 37, Issue 14 , Pages 1752-1758 , September 2001

Article Tools

* Image Usage & Resolution